行情

AGLE

AGLE

Aeglea Bio
NASDAQ

实时行情|Nasdaq Last Sale

7.90
-0.10
-1.25%
盘后: 7.90 0 0.00% 16:00 12/11 EST
开盘
8.07
昨收
8.00
最高
8.38
最低
7.86
成交量
7.58万
成交额
--
52周最高
9.45
52周最低
5.99
市值
2.29亿
市盈率(TTM)
-3.2676
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

AGLE 新闻

  • Aeglea BioTherapeutics (AGLE) Investor Presentation - Slideshow
  • Seeking Alpha - Article.12/04 18:39
  • Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Insiders Increased Their Holdings
  • Simply Wall St..12/03 10:22
  • 意大利最大商业银行拟裁员8000人
  • 新浪财经.12/03 07:12
  • 意大利总理支持欧洲稳定机制改革 遭反对党批评
  • 中国新闻网.12/03 07:11

更多

所属板块

生物技术和医学研究
-0.34%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

AGLE 简况

Aeglea BioTherapeutics, Inc. is a biotechnology company engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. Its lead product candidate, pegzilarginase, is engineered to degrade the amino acid arginine and is being developed to lower arginine levels in patients with Arginase I Deficiency. Its AEB4104 product candidate is a recombinant human enzyme that degrades the amino acid homocysteine and its oxidized form homocystine. It is developing AEB4104 for the treatment of patients with cystathionine beta synthase (CBS) deficiency. Its AEB5100 products candidate is a recombinant human enzyme that degrades plasma cystine and cysteine. It is developing AEB5100 product candidate for the treatment of patients with cystinuria. Its AEB3103 product candidate is an engineered human enzyme that targets the degradation of the amino acid cysteine/cystine.
展开

Webull提供Aeglea Bio Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。